Mel Davis-Pickett is the Head of CMC Technical Development at Immix Biopharma, Inc. Mel possesses more than 16 years of experience in cell therapy analytical development at Bristol Myers Squibb (BMS), and the Fred Hutchison Institute. At BMS, Mel led analytical development activities for three CAR T programs, including Breyanzi®, from early phase through BLA; co-authored a FDA-approved Justification of Specification for Breyanzi ®’s Module 3, championed stability-indicating method development, and guided portfolio prioritization through cross-functional leadership, risk frameworks, and team mentorship across assay platforms. Prior, Mel was a scientist at the Fred Hutchison Cancer Research Center. Mel received a bachelor’s degree in Cell and Molecular Biology & Chemistry from the Evergreen State College.